24224
Brenda Moura, José Silva Cardoso
Bibliografia
1. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur
Heart J ;2012 :33,1787‑1847
2. Cleland J, Tendera M, Adamus J, et al. on behalf of PEP‑CHF Investigators. The perindopril
in elderly people with chronic heart failure (PEP‑CHF) study. Eur Heart J. 2006 ;27:2338‑45
3. Yusuf S, Pfeffer MA, Swedberg K,et al. Effects of candesartan in patients with chronic heart
failure and preserved left‑ventricular ejection fraction: the CHARM‑Preserved Trial. Lancet.
2003;362:777‑81.
4. Massie B, Carson PE, McMurray JJ, et al. Irbesartan for Heart Failure with Preserved Ejection
Fraction. N Engl J Med. 2008; 359:2456‑2467
5. The PEACE Trial Investigators. Angiotensin‑Converting–Enzyme Inhibition in Stable Coro-
nary Artery Disease. N Engl J Med. 2004; 351:2058‑206
6. Efficacy of perindopril in reduction of cardiovascular events among patients with stable
coronary artery disease: randomised, double‑blind, placebo‑controlled, multicentre trial
(the EUROPA study) The EURopean trial On reduction of cardiac events with Perindopril in
stable coronary Artery disease Investigators*. Lancet. 2003;362: 782‑788
7. Danchi, N, Cucherat M, Thuillez C, et al. Angiotensin‑converting enzyme inhibitors in
patients with coronary artery disease and absence of heart failure or left ventricular sys-
tolic dysfunction. an overview of long‑term randomized controlled trials. Arch Intern Med.
2006;166:787‑796
8. Dickstein K, Kjekshus J. OPTIMAAL Steering Committee of the OPTIMAAL Study Group.
Effects of losartan and captopril on mortality and morbidity in high‑risk patients after acute
myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarc-
tion with Angiotensin II Antagonist Losartan. Lancet. 2002;360:752‑60
9. McMurray J, Solomon S, Pieper K, et al. The Effect of valsartan, captopril, or both on ath-
erosclerotic events after acute myocardial infarction. an analysis of the Valsartan in Acute
Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol. 2006;47:726‑33
10. Strauss M, Hall A. Do angiotensin receptor blockers increase the risk of myocardial infarc-
tion? Circulation. 2006;114: 838‑54
